We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$7.48B
AUM Growth
+$1.44B
Cap. Flow
-$77.6M
Cap. Flow %
-1.04%
Top 10 Hldgs %
23.83%
Holding
336
New
58
Increased
161
Reduced
69
Closed
35

Top Sells

Rank Stock Value
1
XMTR icon
Xometry
XMTR
+$57.8M
2
PLD icon
Prologis
PLD
+$56.1M
3
GH icon
Guardant Health
GH
+$44M
4
AXSM icon
Axsome Therapeutics
AXSM
+$44M
5
GLBE icon
Global E Online
GLBE
+$37.6M

Sector Composition

Rank Sector Weight
1 Healthcare 36.37%
2 Technology 22.57%
3 Industrials 20.48%
4 Energy 5.51%
5 Utilities 4.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MAX icon
326
MediaAlpha
MAX
$682M
-17,509
Closed -$165K
OCS icon
327
Oculis Holding
OCS
$680M
-430,000
Closed -$11.4M
OKTA icon
328
Okta
OKTA
$29.7B
-4,505
Closed -$340K
PATH icon
329
UiPath
PATH
$9.46B
-10,716
Closed -$116K
PATK icon
330
Patrick Industries
PATK
$2.67B
-2,265
Closed -$239K
PCOR icon
331
Procore
PCOR
$9.72B
-5,490
Closed -$306K
PLD icon
332
Prologis
PLD
$133B
-427,133
Closed -$56.1M
VEEV icon
333
Veeva Systems
VEEV
$45.2B
-3,066
Closed -$539K
VO icon
334
Vanguard Morningstar Mid-Cap ETF
VO
$109B
-9,612
Closed -$690K
WDS icon
335
Woodside Energy
WDS
$44B
-11,923
Closed -$289K
BBOT
336
BridgeBio Oncology
BBOT
$702M
-541,181
Closed -$4.7M

Similar funds

Eventide Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Eventide Asset Management held 336 positions worth $7.48B, up 24% from $6.05B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management's Q2 2026 filing shows 58 new, 161 increased, 69 reduced and 35 closed positions. Its largest new stake was Avalyn Pharma: 1,375,486 shares worth $45.3M. The largest sale was Xometry, an estimated $57.8M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q2 2026 buy was Avalyn Pharma: 1,375,486 shares worth $45.3M.
  • Eventide Asset Management added most to Cadence Design Systems in Q2 2026, an estimated $29.6M increase.
  • Eventide Asset Management's biggest Q2 2026 reduction was Xometry, cutting an estimated $57.8M.
  • Eventide Asset Management fully exited Prologis in Q2 2026, selling an estimated $56.1M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $7.48B portfolio in Q2 2026.
  • Eventide Asset Management opened 58 new positions and closed 35 in Q2 2026.
  • Eventide Asset Management's portfolio value rose 24% quarter-over-quarter to $7.48B.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.